Clinical Trial: A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07355855) titled 'A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma' on Dec. 30, 2025.

Brief Summary: This study is a prospective, multi-cohort, multi-center clinical trial targeting patients with intermediate-to-high-risk rhabdomyosarcoma who have not previously received systemic anti-tumor treatment. It aims to evaluate the efficacy and safety of all-trans retinoic acid combined with VAC chemotherapy.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Rhabdomyosarcoma

Intervention: DRUG: ATRA+VAC

Cohort 1: Intermediat...